I3PT, CONNECTA Therapeutics, CRG and IMIM receive 2,7 million from the Ministry of Science and Innovation to start Phase IIa of the drug CTH120 for fragile X syndrome

by Instituto de Investigación e Innovación Parc Taulí

The Phase IIa study will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with FXS, the most common form of inherited intellectual disability without a specific treatment

Read more

Exploratory analysis from the phase III INTRIGUE study points to the promise of liquid biopsy in guiding patient selection for targeted therapy and personalized medicine in advanced GIST

by VHIO

Results of exploratory research from the open-label phase III INTRIGUE clinical trial demonstrate the potential utility of circulating tumor DNA (ctDNA) next-generation sequencing (NGS)-based analysis...

Read more

El IIS La Fe lidera un ensayo clínico nacional para pacientes con neuroblastoma

by Instituto de Investigación Sanitaria La Fe

El Instituto de Investigación Sanitaria La Fe (IIS La Fe) ha puesto en marcha un ensayo clínico para mejorar la supervivencia de pacientes diagnosticados con neuroblastoma de alto riesgo en España ...

Read more

New immunotherapy for multiple myeloma proves in the lab to be more effective than CAR-T treatment already in use

by CNIO - Centro Nacional de Investigaciones Oncológicas

The new immunotherapy is based on the so-called STAb cells. It has yet to pass clinical trials and therefore it will be at least two years before it reaches the patients.

Read more

Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovativ...

Read more

El IIS La Fe colabora en un proyecto de la UPV que propone un novedoso enfoque para frenar la degeneración neuromuscular en pacientes con ELA

by Instituto de Investigación Sanitaria La Fe

Un estudio propone un novedoso enfoque para frenar la degeneración neuromuscular en pacientes con Esclerosis Lateral Amiotrófica (ELA). Esta patología provoca la pérdida de neuronas motoras y la p...

Read more

IBIMA Plataforma BIONAND y Plataforma en Nanomedicina se sitúa como uno de los líderes en el ámbito nacional en Investigación Biomédica

by Bionand

El Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND) se consolida como uno de los líderes en el ámbito nacional en investigación en salud. MÃ...

Read more

NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

by Ysios Capital

NorthSea Therapeutics B.V. today announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan live...

Read more

Oncoheroes Biosciences: the pivotal role of non-profits in pediatric drug development

by Oncoheroes Biosciences

Their primary goal is securing the necessary funding to propel the testing of our lead compound, volasertib, in five types of pediatric cancer (Ewing’s sarcoma, alveolar rhabdomyosarcoma, medullobla...

Read more

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

by Oryzon Genomics

yzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the fourth quar...

Read more

Albumin at 4% could benefit patients with chronic kidney disease undergoing cardiac surgery under extracorporeal circulation

by Hospital de la Santa Creu i Sant Pau

A clinical trial analyzed the influence of albumin on the development of acute kidney injury associated with cardiac surgery under extracorporeal circulation (ECC) in patients with preserved preopera...

Read more

ARTHEx Biotech, backed by Columbus Venture Partners, receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiRâ„¢ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

by ARTHEx Biotech

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs backed by Columbus Venture Partners, has announced that the ...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream